Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A Single-Center Prospective Study.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
12
06
2022
received:
12
01
2022
accepted:
23
06
2022
medline:
29
5
2023
pubmed:
29
6
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
To examine and compare disease activity over time in giant cell arteritis (GCA) and Takayasu arteritis (TAK) using multimodal assessment combining clinical, laboratory, and imaging-based testing. Patients with GCA or TAK were enrolled into a single-center prospective, observational cohort at any point in the disease course. Patients underwent standardized assessment, including A total of 126 patients with large vessel vasculitis (GCA = 50; TAK = 76) were evaluated across 319 visits. Clinical disease activity was present in 33% of patients in the second to fifth year of disease and in 24% of patients evaluated >5 years after diagnosis. Active vasculitis by PET was observed in 66% of patients in years 2 to 5 after diagnosis and in 50% of patients enrolled >5 years into disease. PETVASs were consistently higher in GCA than TAK in the early and later phases of disease and significantly decreased over time in GCA but not TAK. Correlations between clinical, laboratory, and imaging findings were complex and varied with disease duration. Disease activity in GCA and TAK is common throughout the disease course. Patterns of vascular PET activity at diagnosis and later in disease differ between GCA and TAK.
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1362-1370Informations de copyright
Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
Références
Kim ES, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart 2018;104:558-65.
Keser G, Aksu K. Diagnosis and differential diagnosis of large-vessel vasculitides. Rheumatol Int 2019;39:169-85.
Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 2017;13:578-92.
Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
Aydin SZ, Direskeneli H, Merkel PA. Assessment of disease activity in large-vessel vasculitis: results of an international Delphi exercise. J Rheumatol 2017;44:1928-32.
Chandran A, Udayakumar PD, Kermani TA, et al. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol 2015;33 Suppl 89:S98-102.
Goel R, Danda D, Joseph G, et al. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in Southern India. Semin Arthritis Rheum 2018;47:718-26.
Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 2013;88:822-30.
Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int 2018;38:569-77.
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28.
Mekinian A, Néel A, Sibilia J, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012;51:882-6.
Muratore F, Pipitone N, Salvarani C. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Rev Clin Immunol 2017;13:345-60.
Hellmich B, Águeda AF, Monti S, et al. Treatment of giant cell arteritis and Takayasu arteritis-current and future. Curr Rheumatol Rep 2020;22:84.
Hoffman GS. Treatment of resistant Takayasu's arteritis. Rheum Dis Clin North Am 1995;21:73-80.
Weyand CM, Goronzy JJ. Clinical practice: giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 2014;371:50-7.
Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol 2011;29 Suppl 64:S86-91.
Van der Geest KS, Treglia G, Glaudemans AW, et al. Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021;48:3886-902.
Gribbons KB, Ponte C, Carette S, et al. Patterns of arterial disease in Takayasu arteritis and giant cell arteritis. Arthritis Care Res (Hoboken) 2020;72:1615-24.
Newman KA, Ahlman MA, Hughes M, et al. Diagnosis of giant cell arteritis in an asymptomatic patient. Arthritis Rheumatol 2016;68:1135.
Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131-7.
Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34.
Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 2017;69:837-45.
Grayson PC, Alehashemi S, Bagheri AA, et al. 18F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol 2018;70:439-49.
Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014;93:194-201.
Ostberg G. Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand Suppl 1972;533:135-59.
Quinn KA, Rosenblum JS, Rimland CA, et al. Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis. Semin Arthritis Rheum 2020;50:71-6.